Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice.
Hepatocellular carcinoma (HCC) is one of the most common cancer-related causes of death, and is chemoresistant to anticancer drugs. Anti-angiogenic therapy has been shown to enhance the efficacy of chemotherapy to treat solid tumors. The aim of the present study was to determine whether endostatin, a potent antiangiogenic agent, could enhance the efficacy of doxorubicin to combat HCC. An endostatin expression plasmid was constructed and its expression in vitro and in vivo was detected after gene transfer. Recombinant endostatin inhibited angiogenesis in the chorioallantoic membrane assay, and showed synergistic effects with doxorubicin in inhibiting the in vitro proliferation of endothelial cells, but not that of tumor cells. Both endostatin gene therapy and doxorubicin suppressed the growth of subcutaneous human HepG2 tumors established in BALB/c nude mice, and tumor angiogenesis. Combination therapy with endostatin gene therapy and doxorubicin showed a stronger effect in suppressing tumor growth, and tumor angiogenesis, than the respective monotherapies. Gene transfer of endostatin down-regulated the expression of both hypoxia-inducible factor-1alpha and vascular endothelial growth factor (VEGF), whereas doxorubicin only down-regulated VEGF expression. Endostatin and doxorubicin synergized to down-regulate VEGF expression. Endostatin and doxorubicin combination therapy warrants investigation as a therapeutic strategy to combat HCC.
Liu
Fengjun
F
Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, China.
Tan
Gang
G
Li
Jie
J
Dong
Xuesong
X
Krissansen
Geoffrey W
GW
Sun
Xueying
X
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D019556:COS Cells; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002460:Cell Line; D045744:Cell Line, Tumor; D002645:Chickens; D002522:Chlorocebus aethiops; D004317:Doxorubicin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D043169:Endostatins / Q000008:administration & dosage / Q000235:genetics*; D018014:Gene Transfer Techniques; D006801:Humans; D015552:Injections, Intralesional; D008114:Liver Neoplasms, Experimental / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics
D000903:Antibiotics, Antineoplastic; D043169:Endostatins; D011994:Recombinant Proteins; D004317:Doxorubicin